Autres langues iX Biopharma Ltd.

Actions

42C

SG1BD9000009

Marché Fermé - Singapore S.E. Autres places de cotation 04:05:20 08/05/2024			Varia. 5j.	Varia. 1 janv.
0,043 ^SGD	-10,42 %		0,00 %	-4,44 %

12/03	Les actions singapouriennes terminent en légère hausse ; les actions de Biopharma grimpent de 2% grâce à l'introduction d'une nouvelle plaquette sublinguale.	MT
12/03	IX Biopharma présente une nouvelle plaquette sublinguale	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer	12/03
IX Biopharma Introduces New Sublingual Wafer	12/03
IX Biopharma Ltd. Announces Development of Semaglutide Sublingual Wafer, Ixb 401, Targeting Diabetes and Obesity Markets	11/03
Singapore Stocks Linger in Red; IX Biopharma's Shares Soar 12% Following Unveiling of Novel Drug Delivery System	05/03
IX Biopharma Unveils Novel Drug Delivery System; Shares Surge 12%	05/03
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	04/03
IX Biopharma Ltd. Unveils Novel NAD Wafers At the Centre for Healthy Longevity Conference 2024	04/03
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	04/03
IX Biopharma Stays in Red in Fiscal H1	06/02
IX Biopharma Ltd. Reports Earnings Results for the Half Year Ended December 31, 2023	05/02
IX Biopharma Unit Ends Wafermine Licensing Deal with Seelos Therapeutics; Shares Tumble 10%	20/11
IX Biopharma Unit Launches Anti Ageing Products in US	02/10/23
IX Biopharma Ltd Announces its Wholly-Owned Subsidiary, Meltmed Inc, Introduces its New Suite of Fast-Dissolving Wafer Products in United States	29/09/23
Singapore Stocks Snap Losing Streak; Oxley Shares Slip 4% on Expected Losses in Fiscal H2, Fiscal 2023	22/08/23
IX Biopharma Trims Losses in Fiscal H2; Shares Jump 17%	22/08/23
IX Biopharma Ltd. Reports Earnings Results for the Full Year Ended June 30, 2023	21/08/23
IX Biopharma Limited Unveils Development of Interferon Wafer to Complement Respiratory Viral Diseases	16/08/23
IX Biopharma Ltd. Announces Change of Registered Office Address	04/08/23
IX Biopharma Issues SG$2 Million Worth of Convertible Bonds to Private Investor	25/07/23
IX Biopharma Ltd. announced that it has received SGD 2 million in funding	24/07/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues iX Biopharma Ltd.

Actions

42C

SG1BD9000009

Autres langues

Filtres